India's GLP-1 medicine market reached Rs 2,215 crore [3] in the 12 months ending July, marking a 235% increase [4] year-on-year.
The surge reflects a critical shift in how India manages obesity and diabetes. As the population faces rising obesity rates, the introduction of more affordable treatment options is beginning to bridge the gap between medical need and patient access.
Vikrant Shrotriya, Managing Director of Novo Nordisk India, said that despite the rapid growth, the current reach is minimal. He said that only 0.1% [1] of obese Indians are currently taking GLP-1 medicines.
This small fraction translates to approximately 250,000 [2] people currently using these medications. The disparity between the total number of obese citizens and those receiving treatment suggests a massive untapped market for pharmaceutical providers.
Market expansion is being driven by several factors. Lower-cost generic versions of semaglutide entered the Indian market in March, making the treatment more accessible to a broader demographic. Additionally, competition has increased with the appearance of Eli Lilly’s tirzepatide-based Mounjaro.
Shrotriya said the market is just scratching the surface. The combination of rising demand and the arrival of competitive pricing models is expected to accelerate the adoption of these therapies across the country.
These medications, which include the well-known Ozempic, work by mimicking hormones that target areas of the brain that regulate appetite and food intake. While originally designed for diabetes, their efficacy in weight loss has driven global demand—a trend now manifesting clearly in the Indian healthcare sector.
“Only 0.1% of obese Indians are currently taking GLP-1 medicines.”
The stark contrast between a 235% growth rate and a 0.1% penetration rate indicates that India is at the very beginning of a major healthcare transition. The entry of generic semaglutide and competitors like Eli Lilly suggests that price, rather than medical awareness, has been the primary barrier. As costs drop, these drugs could move from niche luxury treatments to standard care for millions of Indians facing obesity-related health crises.
